CoChat
Sign Up
Cited by 63Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsClinical Laboratory Practices and Quality Control

Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition

Open access
Park, Jong-Chan, Han, Sun-Ho, Cho, Hyun Jin, Byun, Min Soo, Yi, Dahyun, Choe, Young Min, Kang, Seokjo, Jung, Eun Sun +5 more·2017·Alzheimer's Research & Therapy
DOI 10.1186/s13195-017-0248-8PMC PMC5361707
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Plasma β-amyloid (Aβ) is a potential candidate for an Alzheimer's disease (AD) biomarker because blood is an easily accessible bio-fluid, which can be collected routinely, and Aβ is one of the major hallmarks of AD pathogenesis in the brain. However, the association between plasma Aβ levels and AD diagnosis is still unclear due to the instability and inaccurate measurements of plasma Aβ levels in the blood of patients with AD. If a consistent value of plasma Aβ from the blood can be obtained, this might help determine whether plasma Aβ is a potential biomarker for AD diagnosis. METHODS: We predicted the brain amyloid deposit by measuring the plasma Aβ levels. This cross-sectional study included 353 participants (215 cognitively normal, 79 with mild cognitive impairment, and 59 with AD dementia) who underwent Pittsburgh-compound B positron emission tomography (PiB-PET) scans. We treated a mixture of protease inhibitors and phosphatase inhibitors (MPP) and detected plasma Aβ42 and Aβ40 (MPP-Aβ42 and MPP-Aβ40) in a stable manner using xMAP technology. RESULTS: MPP-Aβ40 and MPP-Aβ42/40 (MPP-Aβs) were significantly different between subjects with positive amyloid deposition (PiB+) and those with negative amyloid deposition (PiB-) (P < 0.0001). Furthermore, MPP-Aβ40 (P < 0.0001, r = 0.23) and MPP-Aβ42/40 ratio (P < 0.0001, r = -0.23) showed significant correlation with global PiB deposition (standardized uptake value ratio). In addition, our integrated multivariable (MPP-Aβ42/40, gender, age, and apolipoprotein E genotypes) logistic regression model proposes a new standard for the prediction of cerebral amyloid deposition. CONCLUSIONS: MPP-Aβ might be one of the potential blood biomarkers for the prediction of PiB-PET positivity in the brain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-017-0248-8

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Deep learning models have uncovered plasma proteomic and metabolomic signatures associated with amyloid burden, tau pathology, and cognitive resilience in presymptomatic individuals.

    “These models have uncovered plasma proteomic and metabolomic signatures associated with amyloid burden, tau pathology, and cognitive resilience in presymptomatic individuals372, 373, 374.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [372]

    The Results (‘MPP-Aβs reflect the pathological load of Aβ in the brain’; page not available) report an association between measured plasma Aβ and cerebral amyloid deposition, including data from cognitively normal participants. The paper does not report deep-learning discovery of proteomic or metabolomic signatures, or findings about tau pathology or cognitive resilience. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. [2]Song H Chang YJ Moon M Park SK Tran PT Hoang VH Lee J Mook-Jung I Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of gamma-secretase activity J Alzheimers Dis 2015 43 797 807 25114069
  2. [3]Jansen WJ Ossenkoppele R Knol DL Tijms BM Scheltens P Verhey FR Visser PJ Amyloid Biomarker Study G Aalten P Aarsland D Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis JAMA 2015 313 1924 1938 10.1001/jama.2015.4668 25988462 PMC4486209 · DOI · Paper page
  3. [6]Cataldo JK Prochaska JJ Glantz SA Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation J Alzheimers Dis 2010 19 465 480 20110594 PMC2906761
  4. [7]Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev. 2003;4:CD004514. 14584018
  5. [8]Pillai JA Verghese J Social networks and their role in preventing dementia Indian J Psychiatry 2009 51 Suppl 1 S22 S28 21416012 PMC3038528
  6. [9]Skoog I Gustafson D Update on hypertension and Alzheimer's disease Neurol Res 2006 28 605 611 10.1179/016164106X130506 16945211 · DOI
  7. [10]Solfrizzi V Panza F Frisardi V Seripa D Logroscino G Imbimbo BP Pilotto A Diet and Alzheimer's disease risk factors or prevention: the current evidence Expert Rev Neurother 2011 11 677 708 10.1586/ern.11.56 21539488 · DOI
  8. [11]Radak Z Hart N Sarga L Koltai E Atalay M Ohno H Boldogh I Exercise plays a preventive role against Alzheimer's disease J Alzheimers Dis 2010 20 777 783 20182027
  9. [12]Kang S Jeong H Baek JH Lee SJ Han SH Cho HJ Kim H Hong HS Kim YH Yi EC PiB-PET imaging-based serum proteome profiles predict mild cognitive impairment and Alzheimer's disease J Alzheimers Dis 2016 53 1563 1576 10.3233/JAD-160025 27392853 · DOI · Paper page
  10. [13]Klunk WE Engler H Nordberg A Wang Y Blomqvist G Holt DP Bergstrom M Savitcheva I Huang GF Estrada S Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 2004 55 306 319 10.1002/ana.20009 14991808 · DOI · Paper page
  11. [14]Hampel H Teipel SJ Fuchsberger T Andreasen N Wiltfang J Otto M Shen Y Dodel R Du Y Farlow M Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment Mol Psychiatry 2004 9 705 710 14699432
  12. [15]Irizarry MC Biomarkers of Alzheimer disease in plasma NeuroRx 2004 1 226 234 10.1602/neurorx.1.2.226 15717023 PMC534932 · DOI
  13. [16]Bisaccia E Berger C DiSpaltro FX Armus S Cahill C Klainer A Viral-specific immunization in AIDS-related complex by photopheresis Ann N Y Acad Sci 1991 636 321 330 10.1111/j.1749-6632.1991.tb33462.x 1686539 · DOI
  14. [17]Lewczuk P Kornhuber J Vanmechelen E Peters O Heuser I Maier W Jessen F Burger K Hampel H Frolich L Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing Exp Neurol 2010 223 366 370 10.1016/j.expneurol.2009.07.024 19664622 · DOI
  15. [18]Pesaresi M Lovati C Bertora P Mailland E Galimberti D Scarpini E Quadri P Forloni G Mariani C Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment Neurobiol Aging 2006 27 904 905 10.1016/j.neurobiolaging.2006.03.004 16638622 · DOI
  16. [19]Graff-Radford NR Crook JE Lucas J Boeve BF Knopman DS Ivnik RJ Smith GE Younkin LH Petersen RC Younkin SG Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease Arch Neurol 2007 64 354 362 10.1001/archneur.64.3.354 17353377 · DOI
  17. [20]Yaffe K Weston A Graff-Radford NR Satterfield S Simonsick EM Younkin SG Younkin LH Kuller L Ayonayon HN Ding J Harris TB Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline JAMA 2011 305 261 266 10.1001/jama.2010.1995 21245181 PMC3108075 · DOI
  18. [21]Blasko I Jellinger K Kemmler G Krampla W Jungwirth S Wichart I Tragl KH Fischer P Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine Neurobiol Aging 2008 29 1 11 10.1016/j.neurobiolaging.2006.09.002 17055615 · DOI
  19. [22]Fukumoto H Tennis M Locascio JJ Hyman BT Growdon JH Irizarry MC Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels Arch Neurol 2003 60 958 964 10.1001/archneur.60.7.958 12873852 · DOI
  20. [23]van Oijen M Hofman A Soares HD Koudstaal PJ Breteler MM Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study Lancet Neurol 2006 5 655 660 10.1016/S1474-4422(06)70501-4 16857570 · DOI · Paper page
  21. [24]Han SH Jung ES Sohn JH Hong HJ Hong HS Kim JW Na DL Kim M Kim H Ha HJ Human serum transthyretin levels correlate inversely with Alzheimer's disease J Alzheimers Dis 2011 25 77 84 21335655
  22. [27]Reyes Barcelo AA Gonzalez-Velasquez FJ Moss MA Soluble aggregates of the amyloid-beta peptide are trapped by serum albumin to enhance amyloid-beta activation of endothelial cells J Biol Eng 2009 3 5 10.1186/1754-1611-3-5 19397812 PMC2683804 · DOI
  23. [28]Milojevic J Melacini G Stoichiometry and affinity of the human serum albumin-Alzheimer's Abeta peptide interactions Biophys J 2011 100 183 192 10.1016/j.bpj.2010.11.037 21190670 PMC3010178 · DOI
  24. [29]Schwarzman AL Goldgaber D Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation Ciba Found Symp 1996 199 146 160 8915609
  25. [31]Kumar S Singh S Hinze D Josten M Sahl HG Siepmann M Walter J Phosphorylation of amyloid-beta peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes J Biol Chem 2012 287 8641 8651 10.1074/jbc.M111.279133 22267728 PMC3318721 · DOI
  26. [32]Hulmes JD Bethea D Ho K Huang S-P Ricci DL Opiteck GJ Hefta SA An investigation of plasma collection, stabilization, and storage procedures for proteomic analysis of clinical samples Clin Proteomics 2004 1 17 31 10.1385/CP:1:1:017 · DOI
  27. [33]Ossenkoppele R Jansen WJ Rabinovici GD Knol DL van der Flier WM van Berckel BN Scheltens P Visser PJ Amyloid PETSG Verfaillie SC Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis JAMA 2015 313 1939 1949 10.1001/jama.2015.4669 25988463 PMC4517678 · DOI · Paper page
  28. [34]Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 1993 43 2412 2414 10.1212/WNL.43.11.2412-a 8232972 · DOI · Paper page
  29. [35]Lee DY Lee KU Lee JH Kim KW Jhoo JH Kim SY Yoon JC Woo SI Ha J Woo JI A normative study of the CERAD neuropsychological assessment battery in the Korean elderly J Int Neuropsychol Soc 2004 10 72 81 14751009
  30. [37]McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH Klunk WE Koroshetz WJ Manly JJ Mayeux R The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 2011 7 263 269 10.1016/j.jalz.2011.03.005 21514250 PMC3312024 · DOI · Paper page
  31. [38]Lee JH Lee KU Lee DY Kim KW Jhoo JH Kim JH Lee KH Kim SY Han SH Woo JI Development of the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries J Gerontol B Psychol Sci Soc Sci 2002 57 P47 P53 10.1093/geronb/57.1.P47 11773223 · DOI
  32. [39]Piccinin AM Muniz-Terrera G Clouston S Reynolds CA Thorvaldsson V Deary IJ Deeg DJ Johansson B Mackinnon A Spiro A 3rd Coordinated analysis of age, sex, and education effects on change in MMSE scores J Gerontol B Psychol Sci Soc Sci 2013 68 374 390 10.1093/geronb/gbs077 23033357 PMC3693608 · DOI
  33. [40]Weiss SJ Tissue destruction by neutrophils N Engl J Med 1989 320 365 376 10.1056/NEJM198902093200606 2536474 · DOI · Paper page
  34. [41]Park JC, Baik SH, Han SH, Cho HJ, Choi H, Kim HJ, Choi H, Lee W, Kim DK, Mook-Jung I. Annexin A1 restores Abeta1-42 -induced blood-brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway. Aging Cell. 2017;16:149-61. PMC5242298 27633771
  35. [42]Fanali G di Masi A Trezza V Marino M Fasano M Ascenzi P Human serum albumin: from bench to bedside Mol Aspects Med 2012 33 209 290 10.1016/j.mam.2011.12.002 22230555 · DOI
  36. [43]Jupin M Michiels PJ Girard FC Spraul M Wijmenga SS NMR metabolomics profiling of blood plasma mimics shows that medium- and long-chain fatty acids differently release metabolites from human serum albumin J Magn Reson 2014 239 34 43 10.1016/j.jmr.2013.11.019 24374750 · DOI
  37. [44]Rangachari V Moore BD Reed DK Sonoda LK Bridges AW Conboy E Hartigan D Rosenberry TL Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate Biochemistry 2007 46 12451 12462 10.1021/bi701213s 17910477 · DOI
  38. [45]Youden WJ Index for rating diagnostic tests Cancer 1950 3 32 35 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 15405679 · DOI
  39. [46]Bibl M Welge V Esselmann H Wiltfang J Stability of amyloid-beta peptides in plasma and serum Electrophoresis 2012 33 445 450 10.1002/elps.201100455 22287174 · DOI
  40. [47]Faurschou M Borregaard N Neutrophil granules and secretory vesicles in inflammation Microbes Infect 2003 5 1317 1327 10.1016/j.micinf.2003.09.008 14613775 · DOI · Paper page
  41. [48]Chertov O Yang D Howard OM Oppenheim JJ Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses Immunol Rev 2000 177 68 78 10.1034/j.1600-065X.2000.17702.x 11138786 · DOI
  42. [49]Desrochers PE Weiss SJ Proteolytic inactivation of alpha-1-proteinase inhibitor by a neutrophil metalloproteinase J Clin Invest 1988 81 1646 1650 10.1172/JCI113500 3259248 PMC442601 · DOI
  43. [50]Boyanton BL Jr Blick KE Stability studies of twenty-four analytes in human plasma and serum Clin Chem 2002 48 2242 2247 12446483
  44. [51]Baker AH Edwards DR Murphy G Metalloproteinase inhibitors: biological actions and therapeutic opportunities J Cell Sci 2002 115 3719 3727 10.1242/jcs.00063 12235282 · DOI
  45. [52]Clark S Youngman LD Palmer A Parish S Peto R Collins R Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studies Int J Epidemiol 2003 32 125 130 10.1093/ije/dyg023 12690023 · DOI
  46. [53]Zimmerman LJ Li M Yarbrough WG Slebos RJ Liebler DC Global stability of plasma proteomes for mass spectrometry-based analyses Mol Cell Proteomics 2012 11 M111 M014340 10.1074/mcp.M111.014340 22301387 PMC3433892 · DOI
  47. [54]Vina J Lloret A Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide J Alzheimers Dis 2010 20 Suppl 2 S527 S533 20442496
  48. [55]Chartier-Harlin MC Parfitt M Legrain S Perez-Tur J Brousseau T Evans A Berr C Vidal O Roques P Gourlet V Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region Hum Mol Genet 1994 3 569 574 10.1093/hmg/3.4.569 8069300 · DOI
  49. [56]Assini A Cammarata S Vitali A Colucci M Giliberto L Borghi R Inglese ML Volpe S Ratto S Dagna-Bricarelli F Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment Neurology 2004 63 828 831 10.1212/01.WNL.0000137040.64252.ED 15365131 · DOI
  50. [57]Lopez OL Kuller LH Mehta PD Becker JT Gach HM Sweet RA Chang YF Tracy R DeKosky ST Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study Neurology 2008 70 1664 1671 10.1212/01.wnl.0000306696.82017.66 18401021 PMC2670993 · DOI

Cited by

Sorted by citations

Authors
Park, J.-C., Han, S.-H., Cho, H. J., Byun, M. S., Yi, D., Choe, Y. M., Kang, S., Jung, E. S., Won, S. J., Kim, E. H., Kim, Y. K., Lee, D. Y., & Mook-Jung, I.
Affiliations
  • Seoul National University (KR)
  • University of Ulsan (KR)
Corresponding author
Lee, Dong Young
ORCID
Venue
Alzheimer's Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2017-03-22
Volume
9
Issue
1
Pages
20-20
ISSN
1758-9193 (ISSN-L)
DOI
10.1186/s13195-017-0248-8
PMC
PMC5361707
OpenAlex
W2599951549
Cited by
63
References
6
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 13 · 2020: 8 · 2019: 10 · 2018: 8 · 2017: 3
FWCI
6.52
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
  • National Research Foundation of Korea (2015R1A2A1A05001794, 2014M3C-7A1046047, 2011-0030738, 2014M3C7A1046042, 2015R1C1A2A01053545)
  • SNU medical school (800-20130066, 800-20130067)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Physiology › Clinical Laboratory Practices and Quality Control
Keywords
plasma amyloid-beta, blood biomarkers, Alzheimer's disease, cerebral amyloid deposition, Pittsburgh compound B PET, protease inhibitors, phosphatase inhibitors, Aβ42/Aβ40 ratio, mild cognitive impairment, APOE genotype
MeSH terms
Aged, Alzheimer Disease, Aniline Compounds, Brain, Cross-Sectional Studies, Female, Humans, Male, Peptide Fragments, Prospective Studies, Thiazoles, Biomarkers, Amyloid beta-Peptides, Radiopharmaceuticals, Positron-Emission Tomography, Plaque, Amyloid, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review